*GARETOSMAB BIOLOGICS LICENSE APPLICATION ACCEPTED FOR FDA PRIORITY REVIEW FOR THE TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
*REGENERON PHARMACEUTICALS INC - FDA DECISION EXPECTED BY AUGUST 2026
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 19-FEB-202612:00:01.253 GMT